Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | MLYCD | O95822 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | POLQ | O75417 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301363 | 0.87 | GPBAR1 (0.42) | GPBAR1MLYCDSCN9ASCN10AADORA3 | |
| SCHEMBL31301619 | 0.87 | MLYCD (0.46) | GPBAR1MLYCDSCN9ASCN10ASCN2A | |
| SCHEMBL31301360 | 0.86 | GPBAR1 (0.53) | GPBAR1MLYCDSCN9ASCN10ASCN2A | |
| SCHEMBL31301446 | 0.82 | DGAT1 (0.49) | GPBAR1MLYCDSCN9ATSPOPOLQ | |
| SCHEMBL31301297 | 0.82 | GPBAR1 (0.40) | GPBAR1MLYCDSCN9ASCN10ASCN2A | |
| SCHEMBL31301526 | 0.81 | GPBAR1 (0.41) | GPBAR1MLYCDSCN9ASCN10ASCN2A | |
| SCHEMBL31301576 | 0.79 | CHEK1 (0.44) | GPBAR1SCN9ASCN10A | |
| SCHEMBL31301522 | 0.79 | GPBAR1 (0.46) | GPBAR1SCN9ASCN10ASCN2A | |
| SCHEMBL31301597 | 0.78 | SCN10A (0.52) | SCN10ASCN2A | |
| SCHEMBL34461781 | 0.76 | HSD17B1 (0.46) | GPBAR1SCN10ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | GPBAR1 803/4885MLYCD 2142/4885SCN9A 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.